St. Charles-Borromee, Canada Clinical Trials
A listing of St. Charles-Borromee, Canada clinical trials actively recruiting patients volunteers.
Found 9 clinical trials
A Study to Assess the Efficacy Safety and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
- 0 views
- 18 Jul, 2021
- +253 other locations
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)
Primary Objective: To demonstrate the efficacy of dupilumab in adult and adolescent participants with primary acquired chronic inducible cold urticaria (ColdU) who remain symptomatic despite the use of an H1-antihistamine Secondary Objectives: To demonstrate the efficacy of dupilumab on primary acquired chronic inducible ColdU disease control To demonstrate the efficacy …
- 0 views
- 16 Jul, 2021
- +30 other locations
Pivotal Study to Assess the Efficacy Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate-or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by Annualized rate of acute moderate and severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on Pre-bronchodilator forced …
- 1142 views
- 14 Jun, 2021
- +453 other locations
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
The purpose of this study is to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in COPD patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple combination therapy of LABA, LAMA and ICS with …
- 176 views
- 21 Jul, 2021
- +173 other locations
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE)
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in COPD participants given as an add on to their optimized maintenance COPD therapy. The maximum duration of participant participation is approximately 57 weeks, consisting of 2 …
- 379 views
- 21 Jul, 2021
- +232 other locations
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile. The Phase 3 portion is an event-driven, randomized, observer blinded, placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation compared …
- 0 views
- 01 Jun, 2021
- +73 other locations
Tezepelumab COPD Exacerbation Study
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- 130 views
- 23 Jul, 2021
- +107 other locations
A Research Study to Compare a New Weekly Insulin Insulin Icodec Used With DoseGuide App and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
This study compares insulin icodec to different daily insulins in people with type 2 diabetes. The study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily. Participants will either get insulin icodec, that participants will have to inject once …
- 0 views
- 21 Jul, 2021
- +154 other locations
Study to Assess the Efficacy Safety and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)
Primary Objective: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former …
- 0 views
- 25 Apr, 2021
- +20 other locations